Pharmaceuticals

Onchocerciasis Treatment Market Growth Expected To Reach $5.12 Billion By 2030 At 6.4% CAGR

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Onchocerciasis Treatment Market Grow Between 2026 And 2030?

The onchocerciasis treatment market size has experienced significant expansion over recent years. It is anticipated to expand from $1.11 billion in 2025 to $1.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical growth can be ascribed to several factors, including the constrained supply of ivermectin and doxycycline in regions affected by the disease, a reliance on distribution channels primarily based in hospitals, a general lack of public awareness regarding onchocerciasis management, inadequacies in preventive chemotherapy programs, and an exclusive dependence on oral formulations.

The onchocerciasis treatment market size is anticipated to experience robust expansion in the coming years. This market is projected to reach $1.59 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. The expected growth during this forecast period stems from factors such as the introduction of moxidectin and long-acting formulations, the widening of online and retail pharmacy distribution channels, the creation of combination therapies, augmented government and NGO financial support for eradication initiatives, and the implementation of community-based preventive strategies. Key developments anticipated over the forecast period encompass the broadening of mass drug administration (mda) programs, the formulation of pediatric and fixed-dose treatments, a heightened emphasis on anti-wolbachia therapies, the integration of both oral and injectable treatment protocols, and an increase in community-based and government-backed treatment campaigns.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

Which Primary Drivers Are Impacting The Onchocerciasis Treatment Market Growth?

The increasing number of patients experiencing eye-related conditions is anticipated to boost the onchocerciasis treatment market moving forward. These eye-associated issues encompass various conditions impacting vision and ocular health, such as infections, injuries, and chronic ailments like glaucoma or cataracts. The rise in individuals with these conditions is primarily linked to greater screen time and extended exposure to digital devices. Onchocerciasis treatment aids in preventing and managing vision loss and blindness by eliminating the parasitic infection responsible for inflammation and damage to ocular tissues. For example, the Centers for Disease Control and Prevention (CDC), a US public health agency, reported in May 2024 that approximately 20.5 million Americans over 40 years old have cataracts in at least one eye, representing 17.2% of that demographic. Projections indicate that nearly 30 million individuals will develop cataracts by 2028. Consequently, the growing prevalence of eye conditions is fueling expansion in the onchocerciasis treatment market. The increasing need for surgical interventions is projected to stimulate growth in the onchocerciasis treatment market in the future. Surgical procedures involve medical actions aimed at removing or repairing disease-damaged tissues, frequently employed when pharmaceutical treatments are ineffective or when complications threaten long-term health. This surge is attributed to the progression of onchocerciasis in some patients to advanced stages, necessitating surgical intervention to avert permanent harm, such as vision impairment or disfigurement. Consequently, healthcare providers are expanding their surgical offerings and investing in advanced techniques, thereby enhancing the overall market for onchocerciasis treatment. For instance, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional organization for board-certified aesthetic plastic surgeons, noted that nearly 35 million aesthetic procedures were performed globally in 2023, marking a 3.4% increase from 2022. The report further indicated a 5.5% rise in surgical procedures, with over 15.8 million procedures conducted by plastic surgeons. Thus, the growing demand for surgical procedures is propelling the onchocerciasis treatment market’s expansion.

How Is The Onchocerciasis Treatment Market Organized By Segment Classification?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

Which Trends Are Shaping The Onchocerciasis Treatment Market?

Leading companies operating in the onchocerciasis treatment market are prioritizing the development of innovative antiparasitic drugs to enhance the effectiveness of treatment and decrease its duration. Antiparasitic medications are pharmaceuticals specifically designed to eliminate or inhibit parasites like worms and protozoa, which are known to cause human infections. For instance, in December 2024, Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company based in Australia, secured approval from the Ghana Food and Drugs Authority (FDA) for its Moxidectin 2 mg oral tablets, intended for treating river blindness in individuals aged 4 years and older. This authorization allows Ghana to conduct community-based mass drug administration programs using moxidectin, which provides superior efficacy and more prolonged effects compared to ivermectin. With this approval, MDGH aims to expand access to an effective new therapy for onchocerciasis, thereby enabling large-scale community initiatives in endemic regions.

Who Are The Industry Participants Involved In The Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Get The Full Onchocerciasis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Where Is The Onchocerciasis Treatment Market Primarily Concentrated By Region?

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Onchocerciasis Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Browse Through More Reports Similar to the Global Onchocerciasis Treatment Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncologists Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795